Stanford Cancer Institute Directory

Population Sciences Profiles

Showing 1 - 2 of 2
    Sr Research Engineer, Medicine - Stanford Prevention Research Center Sr Research Scholar, Medicine - Med/Stanford Prevention Research Center
    Professor (Research) of Medicine (Stanford Prevention Research Center/Cancer Institute) and, by courtesy, of Health Research and Policy (Epidemiology)


    Dr. Hsing is a professor of medicine at Stanford University and a co-leader of the Population Sciences Program at Stanford Cancer Institute. A senior fellow for the Center for Innovation in Global Health at Stanford University, Dr. Hsing has conducted population-based epidemiological studies on four continents, including North and South America, Asia, Africa, and Europe. She is a leading expert in the epidemiology and etiology of prostate, hepatobiliary, and thyroid cancers as well as in hormonal carcinogenesis and circadian rhythm. Throughout her 22-year tenure at National Cancer Institute, Dr. Hsing developed extensive expertise in molecular epidemiology, global oncology, cancer prevention, and population-based studies in international settings. She has served on numerous committees and advisory boards, most recently as a member of the Editorial Board of Cancer Epidemiology, Biomarkers & Prevention and as an academic editor of PLOS ONE. She also has served as an adjunct professor in the Department of Epidemiology and the Department of Urology at the George Washington University in Washington, D.C., as well as in the Department of Public Health of Fu Jen Catholic University’s School of Medicine in Taiwan. Dr. Hsing has authored more than 270 peer-reviewed articles, written seven book chapters, and mentored over 50 post-doctoral fellows and scholars. Dr. Hsing currently serves as PI on the following funded projects: • A pilot study to assess the feasibility of building a population-based cancer registry in Accra, Ghana; • A study to assess patterns and trends of liver cancer in the Greater Bay area and in California and to project liver cancer burden in 20 years; • A pilot study in the Bay area to investigate non-viral factors of liver cancer; • A pilot study to investigate the clinical utility of ctNDA in post-treatment surveillance of liver cancer in Mongolia; • A whole genome sequencing study of aggressive thyroid cancer to identify novel prognostic factors; • A cohort study of 10,000 healthy individuals in Taiwan to investigate social and biochemical determinants of wellness (WELL Taiwan); • A cohort study of 10,000 healthy individuals in China to investigate social and biochemical determinants of wellness (WELL China); • A multiethnic cohort study of 550,000 individuals in Singapore to investigate social and biochemical determinants of wellness (WELL Singapore) She also serves as the Stanford PI of a consortium study of a genome-wide association study (GWAS) of prostate cancer in the African countries of Ghana, Senegal, Nigeria, and South Africa. More recently, her her work involves big data studies using such resources as the National Health Insurance Research Database, SEER-Medicare, and other large administrative claims and medical record databases to identify clinically relevant questions to help inform clinical practice.